Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
India may issue a warning over cough syrup exported by Marion Biotech linked to a death in Uzbekistan.
Read Full NewsMRI offers the possibility of personalized neoadjuvant chemotherapy for patients with HER2-positive breast cancer, but it may not be ready for prime time.
Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.
Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.
A phase 2 study evaluates the safety and efficacy of brexucabtagene autoleucel in BTKi-naïve patients with relapsed/refractory mantle cell lymphoma.
1.
These Athletes Weren't Doping. Their Genes Made It Look Like They Did.
2.
High Success Rate With Conversion Therapy for Unresectable Gastroesophageal Cancer
3.
New protocols, according to a study, allow many patients to safely return home one day after lung cancer surgery.
4.
Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma
5.
Researchers discover cellular 'doorway' exploited by cancer-causing virus
1.
Toripalimab + Nab-Paclitaxel in PD-L1+ TNBC: Phase 3 TORCHLIGHT Trial Results
2.
Unlocking the Secrets of Leukemic Stem Cells: A Path to Better Blood Cancer Treatments
3.
HSC Failure in Fanconi Anemia: Mechanisms, Models, and Emerging Therapeutic Pathways
4.
What You Need To Know About Secondary Polycythemia: Treatment & Symptoms
5.
Vaso Occlusive Crisis: Understanding the Painful Reality of Sickle Cell Disease
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part II
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
3.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
4.
Evolving Space of First-Line Treatment for Urothelial Carcinoma- Case Discussion
5.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge